This dispatch covers Epithalon and Telomere Biology: Current Evidence and Future Directions in the Anti-Aging research category, authored by Khavinson, V., Popovich, I., Anderson, P., originally published in Aging Cell on January 22, 2024. It has been cited 142 times and takes approximately 20 minutes to read. The Peptide Dispatch curates peer-reviewed peptide research for self-directed learners. All summaries are presented for Research Use Only and do not constitute medical advice.
Epithalon (Ala-Glu-Asp-Gly) is a tetrapeptide developed at the St. Petersburg Institute of Bioregulation and Gerontology and has been the subject of a thirty-year research programme spanning in-vitro telomerase induction, rodent lifespan extension, and small human trials in elderly Russian and Ukrainian cohorts. The mechanistic claim — direct induction of telomerase activity in adult somatic cells via TERT-gene expression modulation — would, if independently confirmed, be exceptionally significant in cellular biology. However, replication outside the original research consortium has been limited. Rodent studies report 10-30% lifespan extension; human studies report directional improvement on melatonin secretion, immune-cell counts, and sleep quality, but with small sample sizes and variable blinding. No hard-endpoint Phase 2/3 trials have been published. The theoretical oncological concern raised by inducing telomerase activity in adult somatic cells has not been adequately addressed. Pharmacokinetics in humans are sparse; the peptide is orally inactive. Epithalon is unscheduled by the FDA and not approved for any indication in the US.
Epithalon (Epitalon, Epithalamin) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed in the late 1980s at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson and colleagues. It was designed as a synthetic analog of an endogenous pineal-gland peptide complex hypothesised to regulate circadian and neuroendocrine ageing. Over the subsequent three decades, Epithalon has been the subject of an unusually long-running research programme spanning rodent lifespan studies, in-vitro telomerase induction experiments, and a small number of human clinical investigations conducted predominantly in Russia and Ukraine. This dispatch synthesises the published evidence base, with explicit attention to the methodological strengths and limitations that constrain interpretation. The mechanistic claim that has driven the most external interest is that Epithalon directly induces telomerase activity in somatic cells. The original 2003 in-vitro work by the Khavinson group reported that Epithalon induced measurable telomerase activity in cultured human somatic cells (fibroblasts) that had previously exhausted their replicative capacity, and that telomere elongation could be detected in treated cells over multiple passage cycles. This finding was particularly notable because telomerase induction in adult somatic cells is exceptionally rare outside of stem-cell and germline contexts. Subsequent in-vitro work has reported similar findings in a small number of additional cell lines, but independent replication outside the original research group has been limited. The proposed molecular mechanism involves Epithalon binding to specific sites on chromatin and influencing the expression of the TERT gene that encodes the catalytic subunit of telomerase, although the precise binding interaction has not been crystallographically characterised. The rodent lifespan literature is the most provocative and the most contested. Across multiple long-term studies in mice and …
All information is presented for Research Use Only (RUO). Not medical advice.